Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-10 · accession 0000875320-26-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | 2026-02-10 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $468.41 | -592 | 11.5K | -5% | -$277.3K | |
| 2026-02-12 | 2026-02-11 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $460.43 | -1,376 | 10.1K | -12% | -$633.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-10 | F | D | 592 | $468.41 | 11,503 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-11 | S | D | 1,376 | $460.43 | 10,127 | D | — | — |